Profund Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.77M Buy
73,381
+1,354
+2% +$35.4K 0.05% 226
2026
Q1
$2.02M Sell
72,027
-30,147
-30% -$803K 0.07% 199
2025
Q4
$2.54M Buy
102,174
+16,785
+20% +$423K 0.08% 156
2025
Q3
$2.18M Sell
85,389
-1,988
-2% -$49.1K 0.07% 178
2025
Q2
$2.12M Sell
87,377
-5,010
-5% -$117K 0.08% 175
2025
Q1
$2.34M Sell
92,387
-3,095
-3% -$81K 0.1% 155
2024
Q4
$2.53M Sell
95,482
-13,933
-13% -$378K 0.09% 152
2024
Q3
$3.17M Buy
109,415
+6,849
+7% +$200K 0.12% 135
2024
Q2
$2.87M Sell
102,566
-6,172
-6% -$170K 0.11% 139
2024
Q1
$3.02M Sell
108,738
-6,002
-5% -$167K 0.12% 129
2023
Q4
$3.3M Buy
114,740
+9,889
+9% +$299K 0.14% 121
2023
Q3
$3.48M Sell
104,851
-599
-0.6% -$21.2K 0.19% 90
2023
Q2
$3.87M Buy
105,450
+3,471
+3% +$135K 0.21% 75
2023
Q1
$4.16M Sell
101,979
-707
-0.7% -$30.5K 0.26% 64
2022
Q4
$5.26M Sell
102,686
-50,551
-33% -$2.42M 0.34% 52
2022
Q3
$6.71M Sell
153,237
-9,586
-6% -$466K 0.48% 36
2022
Q2
$8.54M Sell
162,823
-17,344
-10% -$884K 0.54% 31
2022
Q1
$9.33M Sell
180,167
-22,436
-11% -$1.16M 0.39% 41
2021
Q4
$12M Buy
202,603
+14,459
+8% +$716K 0.39% 43
2021
Q3
$8.09M Sell
188,144
-7,492
-4% -$332K 0.27% 60
2021
Q2
$7.66M Buy
195,636
+2,816
+1% +$110K 0.26% 67
2021
Q1
$6.99M Sell
192,820
-10,094
-5% -$358K 0.27% 66
2020
Q4
$7.47M Buy
202,914
+58,691
+41% +$2.15M 0.33% 53
2020
Q3
$5.02M Sell
144,223
-33,842
-19% -$1.19M 0.26% 68
2020
Q2
$5.52M Buy
178,065
+43,200
+32% +$1.47M 0.31% 58
2020
Q1
$4.18M Sell
134,865
-58,544
-30% -$1.99M 0.31% 59
2019
Q4
$7.19M Buy
193,409
+17,704
+10% +$631K 0.31% 54
2019
Q3
$5.99M Sell
175,705
-93,509
-35% -$3.4M 0.3% 55
2019
Q2
$11.1M Sell
269,214
-55,264
-17% -$2.19M 0.52% 29
2019
Q1
$13.1M Buy
324,478
+62,592
+24% +$2.51M 0.63% 27
2018
Q4
$10.8M Sell
261,886
-57,847
-18% -$2.4M 0.67% 23
2018
Q3
$13.4M Buy
319,733
+40,118
+14% +$1.54M 0.51% 27
2018
Q2
$9.63M Sell
279,615
-31,958
-10% -$1.09M 0.38% 39
2018
Q1
$10.5M Sell
311,573
-14,530
-4% -$500K 0.42% 34
2017
Q4
$11.2M Sell
326,103
-84,754
-21% -$2.89M 0.43% 37
2017
Q3
$13.9M Buy
410,857
+13,523
+3% +$435K 0.58% 27
2017
Q2
$12.7M Buy
397,334
+8,024
+2% +$253K 0.57% 24
2017
Q1
$12.6M Buy
389,310
+20,355
+6% +$642K 0.56% 27
2016
Q4
$11.4M Sell
368,955
-39,197
-10% -$1.2M 0.52% 28
2016
Q3
$13.1M Sell
408,152
-5,960
-1% -$199K 0.62% 22
2016
Q2
$13.8M Sell
414,112
-36,275
-8% -$1.16M 0.67% 19
2016
Q1
$12.7M Sell
450,387
-132,010
-23% -$3.77M 0.66% 21
2015
Q4
$17.8M Sell
582,397
-13,250
-2% -$417K 0.85% 19
2015
Q3
$17.8M Sell
595,647
-181,972
-23% -$5.83M 1.01% 16
2015
Q2
$24.7M Buy
777,619
+10,164
+1% +$331K 1.02% 13
2015
Q1
$25.3M Buy
767,455
+18,990
+3% +$604K 0.99% 13
2014
Q4
$22.1M Buy
748,465
+75,032
+11% +$2.15M 0.91% 15
2014
Q3
$18.9M Buy
673,433
+90,787
+16% +$2.55M 0.88% 15
2014
Q2
$16.4M Sell
582,646
-24,860
-4% -$709K 0.72% 16
2014
Q1
$18.5M Buy
607,506
+82,690
+16% +$2.47M 0.84% 14
2013
Q4
$15.3M Buy
524,816
+20,962
+4% +$610K 0.68% 14
2013
Q3
$13.7M Buy
503,854
+1,994
+0.4% +$54.3K 0.73% 14
2013
Q2
$13.3M Buy
+501,860
New +$13.9M 0.94% 12

Other funds holding PFE

Profund Advisors's PFE Position: Q2 2026 in Review

Profund Advisors increased its Pfizer (PFE) stake by 1.9% in Q2 2026, buying an estimated $35.4K and bringing the position to 73,381 shares worth $1.77M. The position accounts for 0.05% of the portfolio, ranked #226.

Profund Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $25.3M in Q1 2015. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Profund Advisors held 73,381 shares of Pfizer worth $1.77M as of Q2 2026.
  • Profund Advisors bought 1,354 Pfizer shares in Q2 2026, an estimated $35.4K.
  • Pfizer made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #226 holding.
  • Profund Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Profund Advisors's Pfizer position peaked at $25.3M in Q1 2015.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.